Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome
- PMID: 16456869
- DOI: 10.1002/cyto.b.20078
Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome
Abstract
Background: ZAP-70 has emerged as a potential pivotal prognostic marker for patients with chronic lymphocytic leukemia (CLL), which could replace immunoglobulin heavy chain mutation status. Although several flow cytometry assays have been described for assessing ZAP-70 in CLL, certain technical and scientific issues remain unsolved, which have prevented results of this crucial test from being reported, even in the best routine flow cytometry laboratories. In this report, we aimed to solve some of these issues by providing a computerized quantitative flow cytometric assay for ZAP-70 within the entire CLL population, which would be easy to perform and enable standardization between laboratories.
Methods: Intracellular ZAP-70 levels in CLL and normal B cells were assessed by molecules of equivalent soluble fluorochrome (MESF), employing Quantum FITC MESF calibration beads to establish a standard curve relating channel value to fluorescence intensity in MESF units and the QuickCal v. 2.2 program (www.bangslabs.com) and clinical relevance of the data was determined.
Results: The average ZAP-70 expression value in the CD19(+)/CD5(+) cells from 35 CLL patients was 103,701 MESF when compared with 12,621 MESF in B cells from 20 normal blood samples. "Low" and "high" ZAP-70 CLL subgroups were defined. Patients with "high ZAP-70 MESF" CLL had a shorter time to disease progression (P = 0.0005) and a more advanced clinical stage (P = 0.0018) when compared with patients in the "low ZAP-70 MESF" CLL subgroup.
Conclusions: This quantitative analysis method can be employed to obtain a more specific and highly accurate assessment of ZAP-70 levels in CLL cells. The method can easily be standardized, in any routine flow laboratory, thereby improving reproducibility and reliability of ZAP-70 analysis.
(c) 2006 International Society for Analytical Cytology.
Similar articles
-
Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied.Cytometry B Clin Cytom. 2006 Jul 15;70(4):242-50. doi: 10.1002/cyto.b.20123. Cytometry B Clin Cytom. 2006. PMID: 16906574
-
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.Cytometry B Clin Cytom. 2006 Jul 15;70(4):270-5. doi: 10.1002/cyto.b.20134. Cytometry B Clin Cytom. 2006. PMID: 16906585
-
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.Cytometry B Clin Cytom. 2006 Jul 15;70(4):309-14. doi: 10.1002/cyto.b.20132. Cytometry B Clin Cytom. 2006. PMID: 16906588
-
[ZAP-70 in B-cell chronic lymphocytic leukemia: clinical significance and methods of detection].Vnitr Lek. 2006 Dec;52(12):1194-9. Vnitr Lek. 2006. PMID: 17299914 Review. Czech.
-
Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.Cytometry B Clin Cytom. 2006 Jul 15;70(4):214-7. doi: 10.1002/cyto.b.20131. Cytometry B Clin Cytom. 2006. PMID: 16906580 Review.
Cited by
-
Detection methods of ZAP-70 in chronic lymphocytic leukemia.Clin Exp Med. 2012 Jun;12(2):69-77. doi: 10.1007/s10238-011-0148-3. Epub 2011 Jun 21. Clin Exp Med. 2012. PMID: 21691729 Review.
-
Cytokine Contents in Chronic Lymphocytic Leukemia: Association with ZAP70 Expression.Turk J Haematol. 2016 Sep 5;33(3):202-8. doi: 10.4274/tjh.2014.0469. Epub 2015 Aug 6. Turk J Haematol. 2016. PMID: 26376785 Free PMC article.
-
CD84 is a survival receptor for CLL cells.Oncogene. 2014 Feb 20;33(8):1006-16. doi: 10.1038/onc.2013.31. Epub 2013 Feb 25. Oncogene. 2014. PMID: 23435417 Free PMC article.
-
Flow Cytometry as a Tool for Quality Control of Fluorescent Conjugates Used in Immunoassays.PLoS One. 2016 Dec 9;11(12):e0167669. doi: 10.1371/journal.pone.0167669. eCollection 2016. PLoS One. 2016. PMID: 27936034 Free PMC article.
-
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.Clin Cancer Res. 2020 Nov 15;26(22):6028-6038. doi: 10.1158/1078-0432.CCR-20-0400. Epub 2020 Sep 11. Clin Cancer Res. 2020. PMID: 32917735 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials